Intravenous @entity619 in acute management of XXXX : a randomized, placebo-controlled, single-blind trial.

@entity1 @entity390 @entity391 @entity619 @entity388
INTRODUCTION: The aim of the present study was to evaluate the role of intravenous @entity619 in relieving the symptoms and signs of @entity388 in the emergency department setting. @entity1 AND METHODS: This was a randomized, placebo-controlled, superiority, single-blind study. @entity1 were randomized either to intravenous @entity619 (group A) or to placebo (group B), with all @entity1 receiving symptomatic therapy. The primary outcome was defined as necessity to hospitalize @entity1 who present with @entity388 in the emergency department. The secondary outcomes were (a) improvement in nystagmus, (b) improvement in postural instability, (c) lessening of @entity390 , (d) @entity391 , and (e) recovery of subjective symptoms. RESULTS: Altogether, 100 @entity1 were randomized, 51 into group A and 49 into group B. There was no difference in the hospitalization rate between groups (P=0.284). In both groups, there was a statistically significant difference in the values of all measured variables 2   h after therapy intervention compared with the baseline values. In group A, significantly fewer @entity1 had third-degree nystagmus 2   h after therapy intervention whereas the difference in group B did not reach statistical significance. After therapy, more @entity1 had first-degree nystagmus in group A as well as in group B than before the intervention. There was a significantly greater absolute difference in European Evaluation of Vertigo scale results in group A compared with group B. CONCLUSION: The value of @entity619 cannot be established, given the small sample and limitations of the present study. Some observations consistent with clinical improvement cannot exclude a true treatment effect, and further study is still warranted.
